Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;8(2):168-171.

The Effect of Low Testosterone and Estrogen Levels on Progressive Coronary Artery Disease in Men

Mansoureh Bajelan  1 , Negar Etehad Roodi  1   2 , Mahdy Hasanzadeh Daloee  3 , Mansoureh Farhangnia  2 , Ali Samadi Kuchaksaraei  1   2
Affiliations

The Effect of Low Testosterone and Estrogen Levels on Progressive Coronary Artery Disease in Men

Mansoureh Bajelan et al. Rep Biochem Mol Biol. 2019 Jul.

Abstract

Background: Age-related morbidity and mortality rates from coronary heart disease (CHD) are higher in men than in women. Abnormal androgen levels cause a variety of abnormal symptoms in men. Testosterone and estrogen are the main sex hormone in men and women, respectively, and studies have shown that they have important roles in cardiovascular health and disease.

Methods: We measured testosterone and estrogen in 102 men with coronary heart disease and 45 controls. Blood samples were collected from subjects and plasma testosterone and estrogen were measured by ELISA.

Results: Men with coronary heart disease had less testosterone (OD Ratio: 0.782) and estrogen (OD Ratio: 0.955) than controls.

Conclusion: Low testosterone and estrogen levels correlate with coronary artery disease.

Keywords: Coronary artery disease; Estrogen; Testosterone.

PubMed Disclaimer

References

    1. Corona G, Maggi M. Testosterone Supplementation and cardiovascular risk. Trends Cardiovasc Med. 2015;25(3):258–60. - PubMed
    1. Scovell J, Ramasamy R, Kovac JR. A critical analysis of testosterone supplementation therapy and cardiovascular risk in elderly men. Can Urol Assoc J. 2014;8(5-6):E356–7. - PMC - PubMed
    1. Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, Maggi M. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13(10):1327–51. - PubMed
    1. Maganty A, Kovac JR, Ramasamy R. The putative mechanisms underlying testosterone and cardiovascular risk. F1000Res. 2014;3:87. - PMC - PubMed
    1. Gencer B, Kohler Ballan B, Philippe J, Mach F. Testosterone: a treatment for the prevention of cardiovascular disease. Rev Med Suisse. 2014;10(432):1173, 8. - PubMed

LinkOut - more resources